SLDB Stock Analysis: Buy, Sell, or Hold?
SLDB - Solid Biosciences Inc. Common Stock
$9.72
-0.70 (-6.72%)
▼
5d:
-12.2%
30d:
+47.05%
90d:
+21.2%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 11, 2026
28d
Get Alerted When SLDB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called SLDB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SLDB is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SLDB is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SLDB is currently trading at $9.72, which is considered slightly high relative to its 30-day fair value range of $7.13 to $10.36.
Technical Outlook: Technically, SLDB is in a uptrend. Immediate support is located at $9.12, while resistance sits at $11.45. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: SLDB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.38 (+78.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SLDB is in a uptrend. Immediate support is located at $9.12, while resistance sits at $11.45. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: SLDB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.38 (+78.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.13 -
$10.36
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.7%)
- BULLISH: Trading 78.9% below Wall St target ($17.38)
- WARNING: Recommendation downgraded due to -12.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$7.13 -
$10.36
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.13
Resistance Level
$11.45
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.97
Wall Street Target
$17.38
(+78.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 13, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLDB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
David T Howton
SELL
7469 shares
2026-02-18
Ilan Ganot
SELL
2658 shares
2026-02-18
Jessie Hanrahan
SELL
4134 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 61 BUY |
